Abstract: The commercialization of cell therapies from the research lab into treatments requires new approaches of biomanufacturing that address challenges of cost, reliability, safety, and durability. The manufacturing of cell products is further complicated by the variability of raw materials and processes that are poorly controlled. There are a number of opportunities offered by microfluidics technologies to lend precision to the biomanufacturing unit operations, as well as in the integration of fluidic pathways to streamline a more continuous manufacturing.